Session » Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: GCA From Bench to Bedside (0891–0896)
- 10:00AM-10:15AM
-
Abstract Number: 0891
MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
- 10:15AM-10:30AM
-
Abstract Number: 0892
Relapse and Immune Dysregulation in Giant Cell Arteritis Are Linked to Mosaic Loss of the Y Chromosome
- 10:30AM-10:45AM
-
Abstract Number: 0893
Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery
- 10:45AM-11:00AM
-
Abstract Number: 0894
Altered B cell subpopulations in Giant Cell Arteritis
- 11:00AM-11:15AM
-
Abstract Number: 0895
Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial
- 11:15AM-11:30AM
-
Abstract Number: 0896
Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?